Concerned about NSI-566 Phase 1 results? Are they statistically significant?
So if I read this right, there were only 18 patients in the trial, completed at just one clinical center? And thus far only one (Ted Harada), that had any significant result? That's a 5% success rate, and with just 18 patients, is that even statistically significant?
Sure, 1 patient that did well is better than none (heck he's walking), but the promise of NSI-566 seems a bit over stated which such a limited data set. It's even more concerning when I see the principal investigator for the study notes the same thing: "In some patients, it appears that the disease is no longer progressing, but it is too early to know if the result from that small number of patients is meaningful." Dr. Feldman is the principal investigator (PI) of the trial and an unpaid consultant to Neuralstem.
The best explanation of where CUR has been and where it is going is in this article:
Please read it. I think it should answer most of your questions. Good Luck
You got that right. This guy can't do the most basic research. It is all over the Neuralstem web site and it is even posted right here on this MB and in the most recent article about the company on SA by Larry Smith. (Which by the way is very detailed and has a very good recap on every single cohort that was treated with NSI-566).
Looking forward to a few very interesting (and positive) trading days ahead for CUR.
I still think we will see $3 to $3.50 before the end of January 2014. In fact, we may see $3 as soon as today or Monday.